AtriCure, Inc. (ATRC) Spending and interest coverage
- R&D / revenue · 12 months: Value 17.21%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.30%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 17.21% | Research and development expense / revenue. Period ending 2026-06-30. $98.03M ÷ $569.62M × 100 ≈ 17.21% |
| Stock-based compensation / revenue · 12 months | 8.30% | Share-based compensation / revenue. Period ending 2026-06-30. $47.27M ÷ $569.62M × 100 ≈ 8.30% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 98.03M USD | Research and Development Expense |
| Revenue | 569.62M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 47.27M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 12.89M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $98.03M | $569.62M | $47.27M | $12.89M | (m) | 17.21% | 8.30% | (m) | (m) |
| 2026-03-31 | $100.92M | $552.16M | $46.33M | $-2.97M | (m) | 18.28% | 8.39% | (m) | (m) |
| 2025-12-31 | $99.21M | $534.53M | $44.69M | $-9.45M | (m) | 18.56% | 8.36% | (m) | (m) |
| 2025-09-30 | $109.66M | $518.30M | $43.81M | $-26.46M | (m) | 21.16% | 8.45% | (m) | (m) |
| 2025-06-30 | $107.73M | $499.95M | $41.75M | $-34.07M | (m) | 21.55% | 8.35% | (m) | (m) |
| 2025-03-31 | $98.86M | $480.08M | $40.77M | $-35.05M | (m) | 20.59% | 8.49% | (m) | (m) |
| 2024-12-31 | $96.18M | $465.31M | $40.41M | $-40.01M | (m) | 20.67% | 8.68% | (m) | (m) |
| 2024-09-30 | $82.02M | $447.57M | $39.33M | $-34.16M | (m) | 18.32% | 8.79% | (m) | (m) |
| 2024-06-30 | $81.41M | $429.95M | $37.63M | $-34.84M | (m) | 18.93% | 8.75% | (m) | (m) |
| 2024-03-31 | $78.43M | $414.60M | $36.23M | $-31.82M | $6.97M | 18.92% | 8.74% | -4.57× | Reported |
| 2023-12-31 | $73.92M | $399.25M | $35.73M | $-26.68M | $6.92M | 18.51% | 8.95% | -3.85× | Reported |
| 2023-09-30 | $66.87M | $380.73M | $33.61M | $-22.15M | $6.69M | 17.56% | 8.83% | -3.31× | Reported |
| 2023-06-30 | $61.68M | $365.69M | $31.95M | $-24.79M | $6.24M | 16.87% | 8.74% | -3.97× | Reported |
| 2023-03-31 | $59.03M | $349.30M | $30.48M | $-34.30M | $5.62M | 16.90% | 8.73% | -6.10× | Reported |
| 2022-12-31 | $57.34M | $330.38M | $28.77M | $-42.67M | $4.99M | 17.35% | 8.71% | -8.56× | Reported |
| 2022-09-30 | $57.40M | $315.57M | $29.11M | $-51.03M | $4.51M | 18.19% | 9.23% | -11.32× | Reported |
| 2022-06-30 | $53.51M | $302.78M | $28.91M | $58.36M | $4.63M | 17.67% | 9.55% | 12.60× | Reported |
| 2022-03-31 | $50.92M | $289.63M | $28.52M | $56.94M | $4.73M | 17.58% | 9.85% | 12.04× | Reported |
| 2021-12-31 | $48.51M | $274.33M | $28.08M | $55.20M | $4.92M | 17.68% | 10.24% | 11.23× | Reported |
| 2021-09-30 | $45.57M | $258.84M | $27.05M | $50.20M | $5.03M | 17.61% | 10.45% | 9.98× | Reported |
| 2021-06-30 | $44.86M | $243.13M | $25.81M | $-52.46M | $4.81M | 18.45% | 10.62% | -10.90× | Reported |
| 2021-03-31 | $42.70M | $212.58M | $24.86M | $-44.66M | $4.85M | 20.09% | 11.70% | -9.22× | Reported |
| 2020-12-31 | $43.07M | $206.53M | $22.64M | $-44.23M | $4.88M | 20.85% | 10.96% | -9.05× | Reported |
| 2020-09-30 | $45.30M | $210.13M | $21.29M | $-42.06M | $4.95M | 21.56% | 10.13% | -8.50× | Reported |
| 2020-06-30 | $44.87M | $211.98M | $20.02M | $-46.70M | $4.83M | 21.17% | 9.45% | -9.67× | Reported |
| 2020-03-31 | $44.64M | $230.07M | $18.21M | $-43.26M | $4.48M | 19.40% | 7.91% | -9.66× | Reported |
| 2019-12-31 | $41.23M | $230.81M | $17.98M | $-33.12M | $4.11M | 17.86% | 7.79% | -8.06× | Reported |
| 2019-09-30 | $36.59M | $222.38M | $17.64M | $-20.40M | $4.17M | 16.45% | 7.93% | -4.89× | Reported |
| 2019-06-30 | $34.99M | $215.71M | $17.60M | $-17.81M | $4.31M | 16.22% | 8.16% | -4.14× | Reported |
| 2019-03-31 | $33.84M | $208.60M | $16.76M | $-13.02M | $4.65M | 16.22% | 8.03% | -2.80× | Reported |
| 2018-12-31 | $34.72M | $201.63M | $16.50M | $-17.13M | $4.61M | 17.22% | 8.18% | -3.72× | Reported |
| 2018-09-30 | $33.99M | $194.80M | $15.33M | $-16.66M | $3.86M | 17.45% | 7.87% | -4.32× | Reported |
| 2018-06-30 | $33.40M | $187.01M | $14.71M | $-17.45M | $3.19M | 17.86% | 7.87% | -5.48× | Reported |
| 2018-03-31 | $33.65M | $180.44M | $14.88M | $-24.77M | $2.53M | 18.65% | 8.24% | -9.79× | Reported |
| 2017-12-31 | $34.14M | $174.72M | $14.62M | $-24.98M | $2.26M | 19.54% | 8.37% | -11.03× | Reported |
| 2017-09-30 | $36.29M | $169.81M | $13.85M | $-30.54M | $2.23M | 21.37% | 8.15% | -13.70× | Reported |
| 2017-06-30 | $36.59M | $166.00M | $13.15M | $-29.98M | $2.18M | 22.04% | 7.92% | -13.73× | Reported |
| 2017-03-31 | $36.81M | $160.44M | $12.48M | $-31.36M | $2.10M | 22.94% | 7.78% | -14.96× | Reported |
| 2016-12-31 | $35.82M | $155.11M | $11.70M | $-31.14M | $1.80M | 23.10% | 7.54% | -17.29× | Reported |
| 2016-09-30 | $33.73M | $149.81M | $11.26M | $-34.07M | $1.51M | 22.51% | 7.52% | -22.61× | Reported |
| 2016-06-30 | $31.96M | $142.90M | $10.72M | $-33.91M | $993.00K | 22.36% | 7.51% | -34.15× | Reported |
| 2016-03-31 | $28.70M | $135.81M | $10.12M | $-31.00M | $533.00K | 21.13% | 7.45% | -58.15× | Reported |
| 2015-12-31 | $25.74M | $129.75M | $9.00M | $-26.72M | $292.00K | 19.84% | 6.93% | -91.51× | Reported |
| 2015-09-30 | $22.97M | $123.31M | $8.40M | $-20.87M | $66.00K | 18.63% | 6.81% | -316.20× | Reported |
| 2015-06-30 | $21.50M | $118.56M | $7.72M | $-15.54M | $74.00K | 18.13% | 6.51% | -210.07× | Reported |
| 2015-03-31 | $20.21M | $112.49M | $7.15M | $-13.58M | $86.00K | 17.96% | 6.36% | -157.90× | Reported |
| 2014-12-31 | $18.60M | $107.45M | $7.57M | $-16.36M | $305.00K | 17.31% | 7.05% | -53.64× | Reported |
| 2014-09-30 | $17.25M | $99.92M | $6.71M | $5.36M | $428.00K | 17.26% | 6.72% | 12.53× | Reported |
| 2014-06-30 | $15.46M | $93.39M | $5.73M | $3.55M | $527.00K | 16.55% | 6.14% | 6.74× | Reported |
| 2014-03-31 | $13.94M | $87.31M | $4.70M | $4.77M | $630.00K | 15.96% | 5.39% | 7.57× | Reported |
| 2013-12-31 | $13.44M | $81.89M | $3.08M | $10.89M | $566.00K | 16.41% | 3.76% | 19.24× | Reported |
| 2013-09-30 | $12.76M | $78.37M | $2.60M | $-7.91M | $614.00K | 16.28% | 3.32% | -12.87× | Reported |
| 2013-06-30 | $12.43M | $74.36M | $2.98M | $-7.82M | $681.00K | 16.71% | 4.00% | -11.48× | Reported |
| 2013-03-31 | $12.26M | $72.20M | $3.30M | $-7.50M | $751.00K | 16.99% | 4.57% | -9.99× | Reported |
| 2012-12-31 | $12.15M | $70.25M | $3.47M | $-7.20M | $802.00K | 17.29% | 4.94% | -8.98× | Reported |
| 2012-09-30 | $12.14M | $68.65M | $3.63M | $-7.04M | $779.43K | 17.69% | 5.29% | -9.03× | Reported |
| 2012-06-30 | $12.31M | $67.73M | $3.23M | $-5.70M | $759.43K | 18.17% | 4.77% | -7.51× | Reported |
| 2012-03-31 | $12.30M | $66.24M | $2.82M | $-5.15M | $730.17K | 18.57% | 4.26% | -7.06× | Reported |
| 2011-12-31 | $11.86M | $64.40M | $2.94M | $-4.73M | $814.43K | 18.41% | 4.56% | -5.81× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $11.53M | $59.01M | $2.77M | $-3.19M | $861.57K | 19.54% | 4.70% | -3.70× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $11.41M | $54.53M | $3.89M | $-15.51M | $812.33K | 20.93% | 7.13% | -19.10× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |